Infection responsive bio-nanoparticles as "molecular sprayer " for infection-repair integration via direct sterilization and macrophage polarization regulation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41323201.
- Also identified by DOI 10.1016/j.bioactmat.2025.10.033 and PMC identifier 12661343.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bone tissue destruction and related complications caused by bacterial infection remain a major challenge in clinical treatment. Existing therapies generally fail to balance the process of infection control and tissue repair simultaneously. In this study, infection microenvironmental-responsive multifunctional "molecular sprayer" nanocomposites (NP@D/AMP) were developed by loading 2-(1, 8-naphthidine -2-yl) phenol (2-NP) onto dendritic mesoporous silica nanoparticles (DMSNs), then encapsulating GW18 with polydopamine for sealing, which achieved the integrated functions of antibacteria, immune regulation and promoting bone formation. NP@D/AMP can sequentially release GW18 and 2-NP under the acidic microenvironment at the infectious site, where GW18 shows strong antibacterial and biofilm inhibition ability against <i>Staphylococcus aureus</i> (<i>S. aureus</i>) and <i>Escherichia coli</i> (<i>E. coli</i>) through electrostatic interaction as well as 2-NP activates macrophages into M1 macrophages to synergistically enhance the antibacterial immune response and improve the inflammatory microenvironment. Notably, NP@D/AMP can also significantly promote osteogenic differentiation <i>in vitro</i> and accelerate bone repair <i>in vivo</i>. In brief, nanocomposite NP@D/AMP has demonstrated sustained and surprising antibacterial activity with macrophage regulation and bone formation efficacy in the treatment model of bone infection. Our study provides an innovative "antibacteria - immune balance - tissue repair" synergistic integrated therapy strategy for infectious bone defects.